Pathology
 |
|
16 december 2018 21:01:47 |
| Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome (Leukemia) |
|
Tweet |
| 68 viewsCategory: Pathology |
 HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia (Leukemia)Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemia (Leukemia) 
|
| blog comments powered by Disqus |
MyJournals.org
The latest issues of all your favorite science journals on one page
The latest issues of all your favorite science journals on one page
